Published in

Elsevier, The Lancet Oncology, 6(20), p. 862-876, 2019

DOI: 10.1016/s1470-2045(19)30178-0

Links

Tools

Export citation

Search in Google Scholar

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Journal article published in 2019 by Ignace Vergote, Giovanni Scambia, David M. O'Malley, Ben Van Calster, Sang-Yoon Park, Josep M. del Campo, Werner Meier, Aristotelis Bamias, Nicoletta Colombo, Robert M. Wenham, Al Covens, Christian Marth, Mansoor Raza Mirza, Judith R. Kroep, Haijun Ma and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO